In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Waystar Holding Corp. (WAY – Research Report), with a price target of $50.00.
Jailendra Singh has given his Buy rating due to a combination of factors surrounding Waystar Holding Corp.’s recent performance and strategic positioning. The company has demonstrated strong results in its first-quarter earnings for 2025, surpassing expectations and prompting an upward revision of its price target from $45 to $50. This positive outlook is further supported by Waystar’s successful integration and retention of clients from Change Healthcare, which has contributed to its core revenue growth.
Additionally, Waystar’s confidence in maintaining a long-term adjusted EBITDA margin of 40% despite a shift towards lower-margin patient payment solutions underscores its operational efficiency. The company’s proactive cost management and increasing use of generative AI are expected to enhance operating leverage over time. These factors, combined with the company’s robust revenue guidance and strategic initiatives, underpin Singh’s Buy rating for Waystar’s stock.
In another report released on May 1, Barclays also maintained a Buy rating on the stock with a $45.00 price target.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WAY in relation to earlier this year.